MicroRNA‑153‑3p suppresses retinoblastoma cell growth and invasion via targeting the IGF1R/Raf/MEK and IGF1R/PI3K/AKT signaling pathways

Abstract

Mounting evidence has demonstrated that microRNAs (miRNAs or miRs) play significant roles in various types of human tumors, including retinoblastoma (RB). However, the biological role and regulatory mechanisms of miRNAs in RB remain to be fully elucidated. The present study was designed to identify the regulatory effects of miRNAs in RB and the underlying mechanisms. Differentially expressed miRNAs in RB tissue were screened out based on the Gene Expression Omnibus (GEO) dataset, GSE7072, which revealed that miR-153 in particular, displayed the highest fold change in expression. It was identified that miR-153 was significantly downregulated in RB tissues, and its downregulation was closely associated with a larger tumor base and differentiation. Functional analysis revealed that the overexpression of miR-153 inhibited RB cell proliferation, migration and invasion, and promoted the apoptosis of WERI-RB-1 and Y79 cells. In addition, insulin-like growth factor 1 receptor (IGF1R) was identified as a target of miR-153 in RB cells. More importantly, it was demonstrated that miR-153 upregulation inhibited the expression of its target gene, IGF1R, which inhibited the activation of the Raf/MEK and PI3K/AKT signaling pathways. Collectively, the present study demonstrates for the first time, to the best of our knowledge, that miR-153 functions as a tumor suppressor in RB by targeting the IGF1R/Raf/MEK and IGF1R/PI3K/AKT signaling pathways. Collectively, the findings presented herein demonstrate that miR-153 targets IGF1R and blocks the activation of the Raf/MEK and PI3K/AKT signaling pathway, thus preventing the progression of RB. Thus, this miRNA may serve as a novel prognostic biomarker and therapeutic target for RB.

Effect of Eriodictyol on Retinoblastoma via the PI3K/Akt Pathway

“…Currently, some studies have reported that the PI3K/Akt pathway plays an important role in RB [ 21 – 23 ]; however, the anticancer effect of eriodictyol on RB has not been reported. The purpose of this study was to investigate the antitumor effect of eriodictyol on the retinoblastoma Y79 cell line and its potential mechanism of action and to provide a new basis for tumor therapy with the PI3K-Akt signaling pathway as a key molecular target.…”

Network pharmacology-based approach to investigate the molecular targets of essential oil obtained from lavender for treating breast cancer

“…IGF1R is a trans -membrane tyrosine kinase receptor and frequently up-regulated in breast cancer [ 27 ]. The interaction between the molecules IGF-I and IGF-II, along with the receptor IGF1R, triggers powerful signals that promote cell growth and prevent cell death via the pathways PI3K/AKT and RAS/MAPK [ 28 ]. It suggests that in luminal breast cancer with a PIK3CA mutation, MAPK1/3 phosphorylation may play a critical role as a downstream effector worth targeting [ 29 ].…”

Centromere protein E as a novel biomarker and potential therapeutic target for retinoblastoma

“…Research into novel biomarkers is an effective way to improve the probability of satisfactory outcomes, including the prognosis and quality of life in patients with retinoblastoma. Although new molecular biomarkers for retinoblastoma have been revealed in recent years [7][8][9][10][11], they are still in the experimental stage and have not been approved for clinical use [12]. Currently, there is no gold standard biomarker for the diagnosis and treatment of retinoblastoma.…”